SAREPTA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.8 USD | -0.36% |
|
-1.38% | +36.70% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,619 | 13,454 | 7,841 | 11,375 | 9,021 | 12,460 | - | - |
| Enterprise Value (EV) 1 | 9,176 | 12,944 | 6,822 | 10,930 | 8,582 | 11,428 | 9,916 | 8,000 |
| P/E ratio | -13.3 x | -24 x | -17.5 x | -16.1 x | -16.6 x | 40.8 x | 13 x | 13.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 25.3 x | 24.9 x | 11.2 x | 12.2 x | 7.26 x | 6.57 x | 4.51 x | 3.82 x |
| EV / Revenue | 24.1 x | 24 x | 9.72 x | 11.7 x | 6.9 x | 6.02 x | 3.59 x | 2.45 x |
| EV / EBITDA | -13.5 x | -24.1 x | -16.2 x | -22.1 x | -38.4 x | 57.7 x | 9.15 x | 3.92 x |
| EV / FCF | -17.8 x | 512 x | -14.2 x | -30.7 x | -14.9 x | -42.2 x | 13.3 x | 25.8 x |
| FCF Yield | -5.62% | 0.2% | -7.06% | -3.26% | -6.72% | -2.37% | 7.52% | 3.87% |
| Price to Book | 11.9 x | 17.4 x | 8.45 x | 29.6 x | 10.5 x | 9.44 x | 4.13 x | 2.53 x |
| Nbr of stocks (in thousands) | 74,543 | 78,913 | 87,077 | 87,783 | 93,547 | 94,524 | - | - |
| Reference price 2 | 129.0 | 170.5 | 90.05 | 129.6 | 96.43 | 131.8 | 131.8 | 131.8 |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 380.8 | 540.1 | 701.9 | 933 | 1,243 | 1,898 | 2,763 | 3,263 |
| EBITDA 1 | -681.1 | -537.3 | -421.7 | -494.3 | -223.4 | 198.2 | 1,084 | 2,041 |
| EBIT 1 | -705.6 | -564.2 | -459.7 | -536.2 | -267.8 | 252.3 | 886.4 | 1,191 |
| Operating Margin | -185.27% | -104.46% | -65.5% | -57.47% | -21.54% | 13.29% | 32.08% | 36.51% |
| Earnings before Tax (EBT) 1 | -713.9 | -553.1 | -418.9 | -690 | -520.1 | 240.1 | 865.9 | 1,196 |
| Net income 1 | -715.1 | -554.1 | -418.8 | -703.5 | -536 | 266.3 | 883.3 | 1,113 |
| Net margin | -187.77% | -102.6% | -59.66% | -75.4% | -43.11% | 14.03% | 31.97% | 34.1% |
| EPS 2 | -9.710 | -7.110 | -5.150 | -8.030 | -5.800 | 3.234 | 10.11 | 9.801 |
| Free Cash Flow 1 | -516.1 | 25.26 | -481.7 | -356.2 | -577.1 | -271 | 745.5 | 310 |
| FCF margin | -135.52% | 4.68% | -68.62% | -38.17% | -46.42% | -14.28% | 26.98% | 9.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 68.8% | 15.19% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 84.4% | 27.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 201.5 | 210.8 | 233.5 | 230.3 | 258.4 | 253.5 | 261.2 | 331.8 | 396.8 | 413.5 | 378.7 | 497.9 | 583.2 | 591.3 | 652.8 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | 71.63 | 121.7 | 215.1 | - | - |
| EBIT 1 | -105.8 | -86.88 | -211.1 | -131.4 | -106.8 | -138.1 | -133.5 | -20.84 | 24.62 | 34.9 | -22.61 | 90.43 | 167 | 171.9 | 233.8 |
| Operating Margin | -52.52% | -41.21% | -90.43% | -57.04% | -41.34% | -54.47% | -51.11% | -6.28% | 6.21% | 8.44% | -5.97% | 18.16% | 28.63% | 29.08% | 35.81% |
| Earnings before Tax (EBT) 1 | -121.9 | -104.1 | -228.1 | -256.4 | -101.3 | -512.7 | -14.58 | -33.17 | 40.37 | 41.45 | -13.62 | 100.8 | 185.8 | 174 | 239 |
| Net income 1 | -122 | -105.3 | -231.5 | -257.7 | -109.2 | -516.8 | -23.94 | -40.94 | 45.66 | 36.12 | -4.21 | 93.62 | 181.1 | 170 | 234 |
| Net margin | -60.55% | -49.95% | -99.14% | -111.93% | -42.27% | -203.85% | -9.16% | -12.34% | 11.51% | 8.74% | -1.11% | 18.8% | 31.05% | 28.75% | 35.84% |
| EPS 2 | -1.420 | -1.200 | -2.650 | -2.940 | -1.240 | -5.860 | -0.2700 | -0.4600 | 0.4700 | 0.3700 | 0.002870 | 0.9712 | 1.808 | 1.352 | 2.170 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/4/22 | 8/2/22 | 11/2/22 | 2/28/23 | 5/2/23 | 8/2/23 | 11/1/23 | 2/28/24 | 5/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 443 | 510 | 1,019 | 445 | 438 | 1,032 | 2,545 | 4,460 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -516 | 25.3 | -482 | -356 | -577 | -271 | 746 | 310 |
| ROE (net income / shareholders' equity) | -77.3% | -70.1% | -49.6% | -40.9% | -86.2% | 34.1% | 53.9% | 46.2% |
| ROA (Net income/ Total Assets) | -41.3% | -23.1% | -13.7% | -8.55% | -1.86% | 9.74% | 16.1% | - |
| Assets 1 | 1,732 | 2,404 | 3,066 | 8,230 | 28,771 | 2,736 | 5,473 | - |
| Book Value Per Share 2 | 10.90 | 9.770 | 10.70 | 4.380 | 9.170 | 14.00 | 31.90 | 52.20 |
| Cash Flow per Share 2 | -6.200 | 1.380 | -5.450 | -3.720 | -5.420 | 2.530 | 13.80 | - |
| Capex 1 | 59.6 | 82.2 | 38.5 | 30.8 | 76.1 | 49.4 | 43.2 | 39.4 |
| Capex / Sales | 15.66% | 15.22% | 5.48% | 3.3% | 6.12% | 2.61% | 1.56% | 1.21% |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
131.8
USD
Average target price
165.9
USD
Spread / Average Target
+25.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.70% | 12.46B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +295.70% | 8.12B |
- Stock Market
- Equities
- SRPT Stock
- Financials Sarepta Therapeutics, Inc.